Status:

COMPLETED

Study to Assess Safety, Tolerability and Pharmacokinetics After Single Doses of AZD2516 to Healthy Volunteers

Lead Sponsor:

AstraZeneca

Conditions:

Healthy

Eligibility:

All Genders

20-80 years

Phase:

PHASE1

Brief Summary

The primary purpose of this study is to assess the safety and tolerability of AZD2516 following administration of a single dose.

Eligibility Criteria

Inclusion

  • Healthy white males or non-fertile females between 20 to 45 years and 65 to 80 years old.
  • Weight between 50 to 100 kg and a body mass index (BMI) between 19 to 28 kg/m2

Exclusion

  • History of previous or ongoing psychiatric disease.
  • Abnormalities in ECG that may interfere with interpretation of data.

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2008

Estimated Enrollment :

72 Patients enrolled

Trial Details

Trial ID

NCT00754715

Start Date

September 1 2008

End Date

December 1 2008

Last Update

December 15 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Research Site

Stockholm, Sweden